Investing Profile

Jason Rhodes

Photo of Jason Rhodes, Partner at Atlas Venture

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
$500K - $5.0M
$2.0M
20
CompanyStageDateRound SizeTotal Raised
Be Biopharma
Series UnknownOct 2024$82M
Series BApr 2022$130M
Series AOct 2020$52M
$260M
Co-investors: Steven Gillis (ARCH Venture Partners), Robert Nelsen (ARCH Venture Partners)
Accent Therapeutics
Series CJan 2024$75M
Series BApr 2020$63M
Series AMay 2018$40M
$180M
Co-investors: Larry Lasky (The Column Group), Naveen Krishnan (Leaps by Bayer)
K36 Therapeutics
Series BJun 2023$70M
Series ADec 2021$30M
$100M
Co-investors: Chong Xu (F-Prime Capital Partners), Melissa McCracken (Nextech Invest)
AAVantgarde Bio
Series AJun 2023$65M
$65M
Co-investors: Paola Pozzi (Soffinova Partners), Graziano Seghezzi (Soffinova Partners), Dmitrij Hristodorov (Forbion), David Steinberg (Longwood Fund)
Rectify Pharmaceuticals
Series AOct 2021$100M
$100M
Co-investors: Marco Boorsma (Forbion), David Steinberg (Longwood Fund), Jodie Morrison (Atlas Venture), Rajesh Devraj (Atlas Venture)
Gemini Therapeutics
Post Ipo EquityFeb 2021$95M
Series AOct 2017$43M
SeedApr 2016$2M
$140M
Co-investors: Stephen Squinto (OrbiMed), Carl Gordon (OrbiMed), Jean George (Advanced Technology Ventures)
Generation Bio
Series CJan 2020$110M
Series AJan 2018$25M
$140M
Third Harmonic Bio
Series AJan 2019$50M
$50M
Co-investors: David Bonita (OrbiMed), Michael Gladstone (Atlas Venture)